- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | OSR Health, Inc.: OSR Health, A Message From the CEO | 303 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / July 13, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from Chief Executive Officer to shareholders.To Every OSR Health Shareholder:OSR Health... ► Artikel lesen | |
| 02.07. | Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target | 417 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / July 2, 2026 / Emerging Growth Research today issued a flash report on OSR Health, Inc. (Nasdaq:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating... ► Artikel lesen | |
| 25.06. | OSR Health, Inc.: OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares | 336 | ACCESS Newswire | Contingent Value Rights would reward continuous holders with additional shares as the Company meets defined price milestones BELLEVUE, WA / ACCESS Newswire / June 25, 2026 / OSR Health, Inc. (NASDAQ:OSRH)... ► Artikel lesen | |
| 22.06. | OSR Holdings changes corporate name to OSR Health | 3 | Investing.com | ||
| 22.06. | OSR Health, Inc.: OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do | 295 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / June 22, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has officially changed its corporate name to OSR Health, Inc., a fresh identity that more directly... ► Artikel lesen | |
| 17.06. | OSR Health ändert Firmennamen - Handelssymbole an der NASDAQ bleiben unverändert | 1 | Investing.com Deutsch | ||
| OSR HEALTH Aktie jetzt für 0€ handeln | |||||
| 17.06. | OSR Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.06. | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | OSR Holdings to acquire VXM01 IP portfolio for $30 million | 2 | Investing.com | ||
| 27.05. | OSR Holdings, Inc.: OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction | 508 | ACCESS Newswire | Transaction Centralizes VXM01 Ownership and Long-Term Royalty Economics at the OSRH Parent Level BELLEVUE, WA / ACCESS Newswire / May 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare... ► Artikel lesen | |
| 13.05. | OSR Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | OSR Holdings rules out reverse stock split amid Nasdaq compliance efforts | 3 | Investing.com | ||
| 12.05. | OSR Holdings, Inc.: CEO Statement to Shareholders | 390 | ACCESS Newswire | A Clear Commitment: No Reverse Stock Split BELLEVUE, WA / ACCESS Newswire / May 12, 2026 / As many of our shareholders are aware, OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A... ► Artikel lesen | |
| 05.05. | OSR Holdings, Inc.: Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target | 550 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / May 5, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target... ► Artikel lesen | |
| 30.04. | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.04. | OSR Holdings, Inc.: OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 | 488 | ACCESS Newswire | OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 BELLEVUE, WA / ACCESS Newswire / April 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding... ► Artikel lesen | |
| 30.04. | OSR Holdings Stock Surges Over 41% After Hours: Why Is It Moving? | 4 | Benzinga.com | ||
| 30.04. | OSR Holdings Executes $815 Million Global License Agreement For VXM01 With BCM Europe | 8 | pulse2.com | ||
| 29.04. | OSR Holdings licenses VXM01 to BCME for up to $815M in milestones | 5 | Investing.com |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,291 | -2,09 % | Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know | ||
| CYTOMX THERAPEUTICS | 3,241 | +1,28 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen | |
| CARISMA THERAPEUTICS INC | 0,028 | 0,00 % | United Immunity Acquires Macrophage Assets from Carisma Therapeutics | ||
| CAPRICOR | 18,190 | +0,44 % | CAPRICOR THERAPEUTICS, INC. - 8-K, Current Report | ||
| CORMEDIX | 7,240 | 0,00 % | CorMedix, Inc.: U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin Patent Litigation | PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 3,818 | +8,34 % | Minerva Neurosciences, Inc: Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs | Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategyBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| REPLIMUNE | 8,682 | +0,51 % | Replimune Group, Inc.: Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma | WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced... ► Artikel lesen | |
| VALERIO THERAPEUTICS | 0,385 | -11,49 % | Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines | The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases... ► Artikel lesen | |
| RANI THERAPEUTICS | 0,645 | -0,69 % | Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates | ~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease molecules ~ ~ Agreement expands Rani's obesity... ► Artikel lesen | |
| IO BIOTECH | 0,048 | 0,00 % | IO Biotech Provides Corporate Update | Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| ALTO NEUROSCIENCE | 27,835 | -0,07 % | Alto Neuroscience platziert Aktien im Wert von 100 Mio. US-Dollar zu 26,48 US-Dollar | ||
| CERO THERAPEUTICS | 0,095 | +0,11 % | NSE - CERO THERAPEUTICS HOLDINGS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ERASCA | 19,500 | 0,00 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| QIAGEN | 36,235 | -0,26 % | Dax legt zu - Qiagen-Aktien gefragt | Frankfurt/Main - Am Donnerstag hat der Dax zugelegt. Zum Xetra-Handelsschluss wurde der Index mit 25.118 Punkten berechnet, ein Plus in Höhe von 0,9 Prozent im Vergleich zum Vortagesschluss. Nach einem... ► Artikel lesen | |
| NEXTCURE | 6,540 | -0,61 % | NextCure-Aktie +300%: Die Hintergründe zum Kurs-Wahnsinn | Die Aktie des US-Biotechunternehmens NextCure hat am Dienstag einen spektakulären Kurssprung hingelegt. Zeitweise schoss das Papier vorbörslich um mehr als 300 Prozent von 2,18 auf rund 9,00 US-Dollar... ► Artikel lesen |
OSR HEALTH INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,362 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HEALTH INC finden Sie auf Wallstreet Online.